Sun Pharma eyes $4 billion loan for Organon buy, five banks likely to anchor refinancing
Sun Pharmaceutical Industries is gearing up to secure a substantial $4 billion syndicated loan aimed at refining its financial structure. This initiative is focused on refinancing a portion of the bridge financing used for its acquisition of Organ...
Five lead arrangers - Citibank, MUFG, Standard Chartered Bank, BNP Paribas and DBS Bank - are looking to commit around $800 million each and are finalising the terms of the facility, which will have a five-year tenor and carry a margin of around 110-120 basis points over the Secured Overnight Financing Rate (SOFR), the people said. SOFR is around 3.9%.
Three to four additional lenders are expected to join the initial group of five lead arrangers during syndication of the takeout facility. The facility agreement will be signed after the syndication process for the senior portion of the loan is completed.
The original bridge financing was backed by a consortium of 12 banks, including MUFG and State Bank of India.

Sun Pharma is also exploring other funding options, including non-convertible debentures, equity and potentially dollar bonds, as part of its overall acquisition financing plan, the sources said.
The company recently raised Rs 7,816 crore through an NCD issue, and a part of the proceeds from that could also be used to repay the bridge financing. The issuer had priced the five-year tranche at 8.05% and the seven-year portion at 8.20%.
Sun Pharma in April announced the proposed acquisition of US-based Organon for an enterprise value of $11.75 billion. The transaction was funded through an 18-month bridge loan.
Organon, a global healthcare company spun off from Merck, reported revenue of $6.2 billion and adjusted operating profit of around $2 billion in calendar year 2025, translating into a healthy operating margin of around 31%, according to a Crisil report. During the first half of calendar year 2026, revenue remained broadly stable on-year over $3 billion, while operating margin sustained around 30%. The transaction has received approval from Organon's shareholders and is expected to be completed over late 2026 and early 2027, subject to requisite regulatory approvals across relevant jurisdictions, the report said.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.